Fellow

Chun-wa Chung is Senior Director of Structural and Biophysical Science at GlaxoSmithKline. As an internationally recognised expert in her field she pioneered many of the integrated biophysical and structural approaches for hit confirmation and fragment-based drug discovery now firmly embedded within medicinal sciences throughout industry and academia. She is widely known for her seminal work on epigenetic proteins, especially the BET bromodomains. Her scientific discoveries and leadership unlocked this previously unexploited target class to enable the design of new inhibitors, with several examples now in clinical trials for oncology and inflammatory disease.